drugset / Trial / NCT03890744
ModraDoc006/r in Patients With Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter phase IIa study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with recurrent or metastatic HER-2 negative breast cancer, that are suitable for treatment with a taxane as 1st-3rd line of therapy.
Timeline
- Start
- 2019-01-30
- Primary completion
- 2020-02-13
- Completion
- 2020-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 10 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |